Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

2(22%)

Results Posted

71%(5 trials)

Phase Distribution

Ph phase_3

67%

Ph phase_1

22%

Ph phase_4

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

2(22.2%)

Phase 3Large-scale testing

6(66.7%)

Phase 4Post-market surveillance

1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(7)

Detailed Status

Completed7

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (22.2%)

Phase 36 (66.7%)

Phase 41 (11.1%)

Trials by Status

active_not_recruiting222%

completed778%

Recent Activity

2 active trials

Showing 5 of 9

active_not_recruitingphase_3

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China

NCT07135986

active_not_recruitingphase_1

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

NCT06647407

completedphase_1

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

NCT06128733

completedphase_3

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

NCT06284915

completedphase_4

Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

NCT05929651

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT07135986Phase 3

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China

Active Not Recruiting

NCT06647407Phase 1

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Active Not Recruiting

NCT06128733Phase 1

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Completed

NCT06284915Phase 3

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

Completed

NCT05929651Phase 4

Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

Completed

NCT03547271Phase 3

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Completed

NCT03537508Phase 3

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Completed

NCT03476135Phase 3

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Completed

NCT03205371Phase 3

Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Completed

All 9 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 9